With the caveat that the analysis is post hoc, here’s the abstract of a paper from a peer-reviewed journal that investigates the association between antibodies to heparin-PF4 complex and death or MI in ACS.
›Role of Anti-PF4/Heparin Antibodies in Recurrent Thrombotic Events After Acute Coronary Syndromes
Seminars in Thrombosis and Hemostasis (2004) 30:347-50.
Mary Ann Mascelli, Efthymios N. Deliargyris, Lakshmi V. Damaraju, Elliot S. Barnathan, David C. Sane
Centocor[a subsidiary of JNJ], Malvern, Pennsylvania; Wake Forest University School of Medicine, Winston-Salem, North Carolina
We postulated that patients with recent acute coronary syndromes and antibodies to the platelet factor 4/heparin complex would have an increased risk of myocardial infarction (MI), even in the absence of thrombocytopenia.
We analyzed sera from patients enrolled in the placebo/unfractionated heparin arm of the GUSTO IV-ACS trial who had a high likelihood of prior heparin exposure. We selected 109 patients without thrombocytopenia with the 30-day primary endpoint (death, MI, or revascularization) and 109 age-, gender-, and race-matched controls who did not achieve the primary endpoint. Twenty-three of 218 patients (10.6%) had anti-PF4/heparin antibodies.
Patients with anti-PF4/heparin were more likely to have death or MI (30.4% vs. 11.3%, p = 0.011) or MI (21.7% vs. 6.2%, p = 0.008) than patients who were negative for the antibody. Antibody-positive patients had higher levels of sVCAM-1 (892 ± 263 µg/L vs. 780 ± 228 µg/L; p = 0.04) and sICAM-1 (246 ± 50 µg/L vs. 222 ± 71 µg/L; p = 0.02) than antibody-negative patients.
In a multiple logistic regression model that included inflammatory markers and clinical risk factors, antibodies to PF4/heparin were a strong predictor of 30-day MI (odds ratio, 9.0; 95% confidence interval [2.1, 38.6]; p < 0.01), with IL-6 being the only other predictor (odds ratio, 1.1; 95% confidence intervals, 1.0 to 1.2; p = 0.03).
Conclusion: Antibodies to the platelet factor 4/heparin complex are a novel, independent predictor of MI at 30 days in patients presenting with acute coronary ischemic syndromes. Antibodies to PF4/heparin are a stronger predictor of MI than clinical characteristics or inflammation markers.‹
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.